search
Back to results

ReachPR Trial Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval

Primary Purpose

Atrioventricular Dyssynchrony, Heart Failure

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Cardiac resynchronization therapy
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrioventricular Dyssynchrony

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Indication for an ICD device according to current guidelines (24);
  • Stable prolonged PR interval >230ms;
  • LVEF (< 35%);
  • New York Heart Association (NYHA) functional class II, III or ambulant IV;
  • Stable sinus rhythm (no documented AF-episodes during the last 4 weeks prior to inclusion);
  • Optimal HF (oral) medication, and on a stable medication scheme at least 1 month prior to enrolment; (2)
  • Age ≥ 18 years and < 80 years.

Exclusion Criteria:

  • Already implanted with an CRT device;
  • Resting Heart rate >90 bpm;
  • Left bundle branch block (LBBB) QRS morphology;
  • QRS duration >150ms
  • Recent myocardial infarction (within 40 days prior to enrolment);
  • Recent coronary artery bypass graft or valve surgery (within 90 days prior to enrolment);
  • Chronic renal failure requiring dialysis;
  • Presence of frequent ventricular premature beats (VPB) (>5% on 24h rhythm monitoring or >2 VPB's on ECG at enrolment);
  • Moderate to severe aortic valve stenosis (AVA<1,5) or a mechanical aortic valve;
  • No femoral arterial access;
  • Second or third degree AV block;
  • Life expectancy < 1 year;
  • Enrolment in one or more ongoing studies that could influence the results of this study.

Sites / Locations

  • Maastricht University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Cardiac resynchronization therapy

Arm Description

AV coupling by atrio-biventricular pacing

Outcomes

Primary Outcome Measures

Left ventricular stroke work
The acute hemodynamic changes in left ventricular stroke work (SW) during atrioventricular optimization by atrio-biventricular pacing.

Secondary Outcome Measures

Full Information

First Posted
May 31, 2019
Last Updated
August 13, 2019
Sponsor
Maastricht University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03973944
Brief Title
ReachPR Trial Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval
Official Title
Restoration of Atrioventricular Coupling by Cardiac Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 18, 2018 (Actual)
Primary Completion Date
December 13, 2019 (Anticipated)
Study Completion Date
December 13, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Rationale: Prolongation of the electrocardiographic PR interval (PR interval > 200ms; also known as first-degree atrioventricular block) is frequently encountered in clinical practice and is generally considered as a benign sign. However, there is increasing evidence that a prolonged PR interval results in poor hemodynamic performance with elevated left ventricular (LV) end-diastolic pressures evidenced by diastolic mitral regurgitation. Previous studies have also associated a prolonged PR interval with a substantially increased risk of future atrial fibrillation (AF) and pacemaker-implantation, and increased risk of heart failure (HF) hospitalization and death. These risks stress the importance of proper atrioventricular (AV) coupling. Shortening of the PR interval may be especially important in heart failure patients and can be obtained by atrioventricular pacing. A possible adverse effect of ventricular pacing is that it results in ventricular dyssynchrony which may lead to worsening cardiac function. This effect may be prevented by applying atrio-biventricular pacing. Data from several previous (sub)studies have suggested this. Objective: The purpose of this study is to investigate the acute hemodynamic effects of restoration of atrioventricular coupling by atrio-biventricular pacing in patients with heart failure and prolonged PR interval. Study design: This study will be a multi-center, exploratory, prospective interventional, nonrandomized acute hemodynamic study, using patients as their own controls. Study population: The study will enroll 26 patients with symptomatic heart failure, reduced left ventricular ejection fraction (LVEF) (< 35%) and prolonged PR interval (>230ms), but without seriously prolonged QRS duration (<150ms) or left bundle branch block (LBBB) QRS pattern, who are candidates for an implantable cardioverter defibrillator (ICD) device according to current guidelines. Main study parameters/endpoints: The main study parameter will be the acute hemodynamic change in left ventricular stroke work (SW) during atrioventricular optimization by atrio-biventricular pacing. Secondary parameters will be the acute hemodynamic changes in left ventricular dP/dt|max and left ventricular stroke volume (SV) by invasive measurements and in left ventricular stroke volume, diastolic mitral regurgitation and left ventricular diastolic filling time by echocardiography during atrioventricular optimization by atrio-biventricular pacing. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The patients are candidates for an ICD device in whom cardiac resynchronization therapy (CRT) can be considered according to current guidelines. Patients in the present study will receive a CRT-defibrillator (CRT-D). The risk and/or complications of the CRT-D implantation are not additional for this study. After the implantation, acute invasive hemodynamic measurements will be performed with a pressure-volume catheter, which is inserted via the femoral artery and adds approximately 30 minutes to the standard procedure. An extra radiation dose of approximately 50mGy is needed to place the pressure volume catheter in the LV cavity. Local vascular complications of femoral artery puncture like bleeding or damage to the vessel wall may occur but are rare. The non-invasive echocardiographic protocol one to two weeks after implantation will add approximately 45 minutes to the routine outpatient clinic visit. The patients do not have to visit the clinic outside the routine outpatient clinic visits before and after a CRT-D implantation. The patients will have the potential direct benefit from the procedure, by finding the patient's specific optimal (atrioventricular) settings and thereby reducing above described risks of a prolonged PR interval. In case of a worse hemodynamic performance due to the procedure, the CRT-D will be programmed to back up pacing and there is no harm for the patient outside the above subscribed extra measurements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrioventricular Dyssynchrony, Heart Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
26 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cardiac resynchronization therapy
Arm Type
Other
Arm Description
AV coupling by atrio-biventricular pacing
Intervention Type
Device
Intervention Name(s)
Cardiac resynchronization therapy
Intervention Description
Atrio-biventricular pacing to shorten the prolonged PR interval
Primary Outcome Measure Information:
Title
Left ventricular stroke work
Description
The acute hemodynamic changes in left ventricular stroke work (SW) during atrioventricular optimization by atrio-biventricular pacing.
Time Frame
Acute measurements (during the cardiac resynchronization therapy device-implantation; duration: approximately 1 hours)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Indication for an ICD device according to current guidelines (24); Stable prolonged PR interval >230ms; LVEF (< 35%); New York Heart Association (NYHA) functional class II, III or ambulant IV; Stable sinus rhythm (no documented AF-episodes during the last 4 weeks prior to inclusion); Optimal HF (oral) medication, and on a stable medication scheme at least 1 month prior to enrolment; (2) Age ≥ 18 years and < 80 years. Exclusion Criteria: Already implanted with an CRT device; Resting Heart rate >90 bpm; Left bundle branch block (LBBB) QRS morphology; QRS duration >150ms Recent myocardial infarction (within 40 days prior to enrolment); Recent coronary artery bypass graft or valve surgery (within 90 days prior to enrolment); Chronic renal failure requiring dialysis; Presence of frequent ventricular premature beats (VPB) (>5% on 24h rhythm monitoring or >2 VPB's on ECG at enrolment); Moderate to severe aortic valve stenosis (AVA<1,5) or a mechanical aortic valve; No femoral arterial access; Second or third degree AV block; Life expectancy < 1 year; Enrolment in one or more ongoing studies that could influence the results of this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Floor Salden, MD
Phone
031 43 38 84520
Email
f.salden@maastrichtuniversity.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Vernooy, MD,PhD
Organizational Affiliation
Maastricht UMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Center
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 HX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Floor Salden, MD
Phone
+31-43-3884520
Email
floor.salden@mumc.nl
First Name & Middle Initial & Last Name & Degree
Frits Prinzen, PhD
First Name & Middle Initial & Last Name & Degree
Floor Salden, MD
First Name & Middle Initial & Last Name & Degree
Kevin Vernooy, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

ReachPR Trial Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval

We'll reach out to this number within 24 hrs